Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection

Sabryna Nantel, Benoîte Bourdin, Kelsey Adams, Julie Carbonneau, Henintsoa Rabezanahary, Marie-Ève Hamelin, Deirdre McCormack, Patrice Savard, Yves Longtin, Matthew P. Cheng, Gaston De Serres, Jacques Corbeil, Vladimir Gilca, Mariana Baz, Guy Boivin, Caroline Quach, Hélène Decaluwe
doi: https://doi.org/10.1101/2022.03.29.22272714
Sabryna Nantel
1Cytokines and Adaptive Immunity Lab, Sainte-Justine University Hospital and Research Center, Montréal, QC, Canada
2Microbiology, Infectiology and Immunology Department, Faculty of Medicine, University of Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benoîte Bourdin
1Cytokines and Adaptive Immunity Lab, Sainte-Justine University Hospital and Research Center, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelsey Adams
3Sainte-Justine University Hospital and Research Center, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Carbonneau
4Infectious Disease Research Center, Université Laval, Québec City, QC, Canada
5CHU de Québec - Université Laval Research Center, Québec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henintsoa Rabezanahary
4Infectious Disease Research Center, Université Laval, Québec City, QC, Canada
5CHU de Québec - Université Laval Research Center, Québec City, QC, Canada
12Microbiology, Infectiology and Immunology Department, Université Laval, Québec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Ève Hamelin
4Infectious Disease Research Center, Université Laval, Québec City, QC, Canada
5CHU de Québec - Université Laval Research Center, Québec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deirdre McCormack
3Sainte-Justine University Hospital and Research Center, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice Savard
2Microbiology, Infectiology and Immunology Department, Faculty of Medicine, University of Montréal, QC, Canada
6Montreal University Hospital and Research Center, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Longtin
7Jewish General Hospital, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew P. Cheng
8Divisions of Infectious Diseases and Medical Microbiology, Departments of Medicine and Laboratory Medicine, McGill University Health Center, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaston De Serres
5CHU de Québec - Université Laval Research Center, Québec City, QC, Canada
9Institut National de Santé Publique du Québec, Québec City, QC, Canada
10Preventive and Social Medicine Department, Université Laval, Québec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Corbeil
5CHU de Québec - Université Laval Research Center, Québec City, QC, Canada
11Molecular Medicine Department, Université Laval, Québec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Gilca
5CHU de Québec - Université Laval Research Center, Québec City, QC, Canada
9Institut National de Santé Publique du Québec, Québec City, QC, Canada
10Preventive and Social Medicine Department, Université Laval, Québec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariana Baz
4Infectious Disease Research Center, Université Laval, Québec City, QC, Canada
5CHU de Québec - Université Laval Research Center, Québec City, QC, Canada
12Microbiology, Infectiology and Immunology Department, Université Laval, Québec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy Boivin
4Infectious Disease Research Center, Université Laval, Québec City, QC, Canada
5CHU de Québec - Université Laval Research Center, Québec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Quach
2Microbiology, Infectiology and Immunology Department, Faculty of Medicine, University of Montréal, QC, Canada
3Sainte-Justine University Hospital and Research Center, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hélène Decaluwe
1Cytokines and Adaptive Immunity Lab, Sainte-Justine University Hospital and Research Center, Montréal, QC, Canada
2Microbiology, Infectiology and Immunology Department, Faculty of Medicine, University of Montréal, QC, Canada
13Pediatric Immunology and Rheumatology Division, Department of Pediatrics, University of Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: helene.decaluwe@umontreal.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. We present detailed immunological evidence to clarify the requirements for one-or two-dose primary vaccination series for naturally primed individuals.

Objective Evaluate the immune response to COVID-19 mRNA vaccines in healthcare workers (HCWs) who recovered from a SARS-CoV-2 infection.

Design Multicentric observational prospective cohort study of HCWs with a PCR-confirmed SARS-CoV-2 infection designed to evaluate the dynamics of T and B cells immune responses to primary infection and COVID-19 mRNA vaccination over 12 months.

Participants Unvaccinated HCWs with PCR-confirmed SARS-CoV-2 infection were selected based on the presence or absence of symptoms at infection and serostatus at enrollment. Age- and sex-matched adults not infected with SARS-CoV-2 prior to vaccination were included as naïve controls.

Exposure Vaccination with Pfizer BioNTech BNT162b2 mRNA vaccine.

Main Outcome(s) and Measure(s) Immunity score (zero to three), before and after vaccination, based on anti-RBD IgG ratio, serum capacity to neutralize live virus and IFN-γ secretion capacity in response to SARS-CoV-2 peptide pools above the positivity threshold for each of the three assays. We compared the immunity score between groups based on subjects’ symptoms at diagnosis and/or serostatus prior to vaccination.

Results None of the naïve participants (n=14) showed a maximal immunity score of three following one dose of vaccine compared to 84% of the previously infected participants (n=55). All recovered individuals who did not have an immunity score of three were seronegative prior to vaccination, and 67% had not reported symptoms resulting from their initial infection. Following one dose of vaccine, their immune responses were comparable to naïve individuals, with significantly weaker responses than those who were symptomatic during infection.

Conclusions and Relevance Individuals who did not develop symptoms during their initial SARS-CoV-2 infection and were seronegative prior to vaccination present immune responses comparable to that of naïve individuals. These findings highlight the importance of administering the complete two-dose primary regimen and following boosters of mRNA vaccines to individuals who experienced asymptomatic SARS-CoV-2 infection.

Question Is a single dose of COVID-19 mRNA vaccine sufficient to induce robust immune responses in individuals with prior SARS-CoV-2 infection?

Findings In this cohort of 55 health care workers previously infected with SARS-CoV-2, we show that the absence of symptoms during initial infection and negative serostatus prior to vaccination predict the strength of immune responses to COVID-19 mRNA vaccine. Lack of symptoms and a negative serostatus prior to vaccination leads to immune responses comparable to naïve individuals.

Meaning Our results support a two-dose primary series requirement for any individual with prior history of asymptomatic SARS-CoV-2 infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the Canadian Institutes of Health Research (CIHR) (VR2172712) and the COVID19 Immunity Task Force/Public Health Agency of Canada. This work has been supported by NIH contract 75N93019C00065 (A.S, D.W).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

RECOVER protocols were approved by the Research Ethics Board (REB) at the Sainte-Justine University Hospital and Research Center under study MP-21-2021-3035 and in each of the five participating centers in the Province of Quebec.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Designates (2) shared senior authorship

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 02, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection
Sabryna Nantel, Benoîte Bourdin, Kelsey Adams, Julie Carbonneau, Henintsoa Rabezanahary, Marie-Ève Hamelin, Deirdre McCormack, Patrice Savard, Yves Longtin, Matthew P. Cheng, Gaston De Serres, Jacques Corbeil, Vladimir Gilca, Mariana Baz, Guy Boivin, Caroline Quach, Hélène Decaluwe
medRxiv 2022.03.29.22272714; doi: https://doi.org/10.1101/2022.03.29.22272714
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection
Sabryna Nantel, Benoîte Bourdin, Kelsey Adams, Julie Carbonneau, Henintsoa Rabezanahary, Marie-Ève Hamelin, Deirdre McCormack, Patrice Savard, Yves Longtin, Matthew P. Cheng, Gaston De Serres, Jacques Corbeil, Vladimir Gilca, Mariana Baz, Guy Boivin, Caroline Quach, Hélène Decaluwe
medRxiv 2022.03.29.22272714; doi: https://doi.org/10.1101/2022.03.29.22272714

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (433)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8982)
  • Forensic Medicine (4)
  • Gastroenterology (419)
  • Genetic and Genomic Medicine (1949)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1328)
  • Health Policy (659)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10800)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1825)
  • Nursing (109)
  • Nutrition (272)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (997)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (579)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1896)
  • Public and Global Health (4120)
  • Radiology and Imaging (675)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (80)